Journal article
Circulating cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-seq) in oncology: from technological advances to clinical applications
NPJ precision oncology, Vol.10(1), p.318
05/25/2026
DOI: 10.1038/s41698-026-01507-w
PMID: 42185453
Abstract
Circulating cell-free DNA (cfDNA) methylation profiling enables minimally invasive cancer detection and monitoring. Among available methods, cfMeDIP-seq is a sensitive, scalable, bisulfite-free approach suitable for low-input cfDNA. This review summarizes its principles, comparative technologies, and clinical applications, including early detection, tumor classification, and minimal residual disease monitoring. Despite promising performance, challenges remain in standardization and validation, while emerging multi-omic integrations may further enhance its role in precision oncology.
Details
- Title: Subtitle
- Circulating cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-seq) in oncology: from technological advances to clinical applications
- Creators
- Edoardo Francini - University of FlorenceSara Bleve - Istituto Scientifico Romagnolo per lo Studio e la Cura dei TumoriGiuseppe Nicolo Fanelli - University of PisaMara Serena Serafini - Cornell UniversityFilippo Pederzoli - Cornell UniversityAlessandra Ferri - Cornell UniversityErika Minonne - Cornell UniversityJacopo Venturini - Sarah Cannon Research InstituteSilvia Rodrigues - Cornell UniversityHubert Pakula - Cornell UniversityCristian Lolli - Istituto Scientifico Romagnolo per lo Studio e la Cura dei TumoriMassimo Cristofanilli - Cornell UniversityPier Vitale Nuzzo - Cornell University
- Resource Type
- Journal article
- Publication Details
- NPJ precision oncology, Vol.10(1), p.318
- DOI
- 10.1038/s41698-026-01507-w
- PMID
- 42185453
- ISSN
- 2397-768X
- eISSN
- 2397-768X
- Publisher
- Nature Publishing Group
- Language
- English
- Date published
- 05/25/2026
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985221147702771
Metrics
1 Record Views